HC Wainwright reaffirmed their buy rating on shares of CalciMedica (NASDAQ:CALC – Free Report) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.
Separately, Oppenheimer reaffirmed an outperform rating and set a $14.00 target price on shares of CalciMedica in a report on Monday, April 1st.
Read Our Latest Research Report on CALC
CalciMedica Trading Up 25.7 %
CalciMedica (NASDAQ:CALC – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07. As a group, equities analysts forecast that CalciMedica will post -2.05 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. BML Capital Management LLC lifted its stake in CalciMedica by 10.3% in the 1st quarter. BML Capital Management LLC now owns 160,424 shares of the company’s stock valued at $667,000 after purchasing an additional 15,000 shares during the last quarter. Meritage Portfolio Management increased its position in shares of CalciMedica by 360.0% during the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after acquiring an additional 36,000 shares in the last quarter. Finally, Hudson Bay Capital Management LP purchased a new position in CalciMedica in the third quarter valued at about $432,000.
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Featured Articles
- Five stocks we like better than CalciMedica
- Investing in the High PE Growth Stocks
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- The 3 Best Blue-Chip Stocks to Buy Now
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Consumer Staples Stocks, Explained
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.